Adam Friedman, Antares Therapeutics CEO
June 10, 2025 08:00 AM EDT
Financing
Startups

Ex­clu­sive: Scor­pi­on spin­out gets $177M for stealthy pipeline amid Chi­na com­pe­ti­tion

Kyle LaHucik

Biotech Correspondent

BOSTON – Antares Ther­a­peu­tics is in a unique po­si­tion.

The Boston and South San Fran­cis­co biotech said Tues­day it’s raised a $177 mil­lion Se­ries A …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Have sky-high sales pro­jec­tions set the obe­si­ty mar­ket up to fail?

Vaxart shares surge on norovirus vac­cine da­ta as it seeks fund­ing for new tri­als

Up­dat­ed: No­vo makes an­oth­er car­diometa­bol­ic deal fo­cused on oral med­i­cines

Ver­tex lays off 125 work­ers af­ter type 1 di­a­betes cell ther­a­py failed study in March

Ca­balet­ta Bio shares CAR-T re­sults in three au­toim­mune con­di­tions

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times